Verdant PhytoMed — Financial Projections
The following financial projections are based on management’s best estimates and assumptions regarding production capacity, pricing, cost structure, and market conditions. All figures are presented in South African Rand (ZAR) millions unless otherwise stated. The projections have been prepared on a basis…
Section 10 · Business Plan
Financial Projections
The following financial projections are based on management’s best estimates and assumptions regarding production capacity, pricing, cost structure, and market conditions. All figures are presented in South African Rand (ZAR) millions unless otherwise stated. The projections have been prepared on a basis…
Growing from ZAR 25 million in Year 1, at a 44% Year-5 EBITDA margin, with an NPV of ZAR 185 million (at a 15% discount rate) and a 3.2-year payback.
The following financial projections are based on management’s best estimates and assumptions regarding production capacity, pricing, cost structure, and market conditions. All figures are presented in South African Rand (ZAR) millions unless otherwise stated. The projections have been prepared on a basis consistent with International Financial Reporting Standards (IFRS) applicable to private companies in South Africa.
10.1 Key Assumptions
| Assumption | Basis |
|---|---|
| Exchange Rate | ZAR 18.50 per EUR (conservative; current ~ZAR 19.20) |
| Dried Flower Price (Y1–Y3) | ZAR 55/gram average (FOB), declining 5% p.a. from Y4 |
| Extract Price | ZAR 300/gram average, stable |
| Production Yield | Per cultivation model; 3–4 cycles/year at maturity |
| COGS as % of Revenue | 45% (Y1), declining to 38% (Y5) via scale efficiencies |
| Staff Costs | 35 FTEs (Y1) scaling to 160 FTEs (Y5); avg. cost ZAR 350K p.a. |
| Inflation | 5.5% p.a. on operating costs |
| Tax Rate | 27% corporate tax rate (SA standard) |
| Depreciation | Straight-line over 10–20 years (infrastructure), 5–7 years (equipment) |
| Capex Schedule | ZAR 95M (Y1), ZAR 15M (Y2), ZAR 12M (Y3), ZAR 18M (Y4), ZAR 10M (Y5) |
10.2 Projected Profit & Loss Statement
| ZAR Millions | Year 1 | Year 2 | Year 3 | Year 4 | Year 5 |
|---|---|---|---|---|---|
| Revenue | 25.0 | 95.0 | 180.0 | 260.0 | 340.0 |
| Cost of Goods Sold | (11.3) | (42.8) | (75.6) | (104.0) | (129.2) |
| Gross Profit | 13.7 | 52.2 | 104.4 | 156.0 | 210.8 |
| Gross Margin (%) | 55% | 55% | 58% | 60% | 62% |
| Staff Costs | (12.3) | (19.5) | (28.5) | (39.0) | (48.0) |
| Operating Expenses | (6.2) | (8.5) | (12.8) | (16.5) | (19.2) |
| Regulatory & Compliance | (3.5) | (2.5) | (2.0) | (1.8) | (1.5) |
| Marketing & Export Costs | (1.7) | (3.2) | (4.6) | (5.7) | (6.1) |
| EBITDA | (10.0) | 20.0 | 65.0 | 104.0 | 150.0 |
| EBITDA Margin (%) | (40%) | 21% | 36% | 40% | 44% |
| Depreciation & Amortisation | (5.5) | (7.0) | (8.5) | (9.5) | (10.0) |
| EBIT | (15.5) | 13.0 | 56.5 | 94.5 | 140.0 |
| Interest Expense | (3.6) | (3.2) | (2.5) | (1.8) | (1.0) |
| Profit Before Tax | (19.1) | 9.8 | 54.0 | 92.7 | 139.0 |
| Income Tax (27%) | 0.0 | (2.6) | (14.6) | (25.0) | (37.5) |
| Net Profit / (Loss) | (19.1) | 7.2 | 39.4 | 67.7 | 101.5 |
| Net Margin (%) | (76%) | 7.6% | 21.9% | 26.0% | 29.9% |
10.3 Projected Balance Sheet
| ZAR Millions | Year 1 | Year 2 | Year 3 | Year 4 | Year 5 |
|---|---|---|---|---|---|
| ASSETS | |||||
| Property, Plant & Equipment | 89.5 | 97.5 | 101.0 | 109.5 | 109.5 |
| Intangible Assets (Licences) | 5.0 | 4.5 | 4.0 | 3.5 | 3.0 |
| Inventory | 3.5 | 7.5 | 14.0 | 20.0 | 26.0 |
| Trade Receivables | 4.2 | 12.0 | 22.5 | 32.5 | 42.5 |
| Cash & Equivalents | 7.0 | (3.0) | 10.5 | 55.5 | 145.0 |
| Other Current Assets | 8.8 | 6.5 | 13.0 | 14.0 | 14.0 |
| Total Assets | 118.0 | 125.0 | 165.0 | 235.0 | 340.0 |
| EQUITY & LIABILITIES | |||||
| Share Capital | 84.0 | 84.0 | 84.0 | 84.0 | 84.0 |
| Retained Earnings | (10.0) | (2.8) | 36.6 | 104.3 | 205.8 |
| Reserves | 0.0 | 7.8 | 23.4 | 44.7 | 58.2 |
| Total Equity | 74.0 | 89.0 | 144.0 | 233.0 | 348.0 |
| Long-term Debt | 36.0 | 28.0 | 15.0 | 0.0 | 0.0 |
| Trade Payables | 5.0 | 5.5 | 3.5 | 1.0 | (10.0) |
| Other Current Liabilities | 3.0 | 2.5 | 2.5 | 1.0 | 2.0 |
| Total Liabilities | 44.0 | 36.0 | 21.0 | 2.0 | (8.0) |
| Total Equity & Liabilities | 118.0 | 125.0 | 165.0 | 235.0 | 340.0 |
10.4 Projected Cash Flow Statement
| ZAR Millions | Year 1 | Year 2 | Year 3 | Year 4 | Year 5 |
|---|---|---|---|---|---|
| OPERATING ACTIVITIES | |||||
| Net Profit / (Loss) | (19.1) | 7.2 | 39.4 | 67.7 | 101.5 |
| Add: Depreciation & Amortisation | 5.5 | 7.0 | 8.5 | 9.5 | 10.0 |
| Change in Working Capital | (4.4) | (2.2) | 4.1 | 10.8 | 18.5 |
| Net Operating Cash Flow | (18.0) | 12.0 | 52.0 | 88.0 | 130.0 |
| INVESTING ACTIVITIES | |||||
| Capital Expenditure | (95.0) | (15.0) | (12.0) | (18.0) | (10.0) |
| Net Investing Cash Flow | (95.0) | (15.0) | (12.0) | (18.0) | (10.0) |
| FINANCING ACTIVITIES | |||||
| Equity Raised | 84.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Debt Raised / (Repaid) | 36.0 | (8.0) | (13.0) | (15.0) | 0.0 |
| Interest Paid | (3.6) | (3.2) | (2.5) | (1.8) | (1.0) |
| Dividends Paid | 0.0 | 0.0 | 0.0 | 0.0 | (19.0) |
| Net Financing Cash Flow | 116.4 | (11.2) | (15.5) | (16.8) | (20.0) |
| Net Cash Movement | 3.4 | (14.2) | 24.5 | 53.2 | 100.0 |
| Opening Cash Balance | 0.0 | 3.4 | (10.8) | 13.7 | 66.9 |
| Closing Cash Balance | 3.4 | (10.8) | 13.7 | 66.9 | 166.9 |
10.5 Investment Returns & Valuation
| Metric | Value |
|---|---|
| Internal Rate of Return (IRR) | ~28% (5-year base case) |
| Net Present Value (NPV @ 15% discount) | ZAR 185 million |
| Payback Period | 3.2 years |
| Year 5 EBITDA Multiple (8x) | ZAR 1.2 billion implied enterprise value |
| Return on Equity (Year 5) | 29.2% |
| Debt-to-Equity Ratio (Year 3) | 0.15x (conservative leverage) |
10.6 Sensitivity Analysis
The following table illustrates the sensitivity of the Company’s Year 3 EBITDA to key variable changes:
| Variable | Base Case | Downside (-20%) | Upside (+20%) |
|---|---|---|---|
| Selling Price (ZAR/g) | 55 | 44 | 66 |
| Year 3 Revenue (ZAR M) | 180 | 144 | 216 |
| Year 3 EBITDA (ZAR M) | 65 | 29 | 101 |
| Year 3 EBITDA Margin | 36% | 20% | 47% |
| Breakeven Year | Year 2 | Year 3 | Year 1 |
This document contains proprietary and confidential information. Distribution without written consent is prohibited.